ClinicalTrials.gg
CompletedNCT05653479Updated Sep 3, 2024Results posted

Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults

A Phase 1 interventional study of UPB-101 in Healthy, sponsored by Upstream Bio Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-03.

Sponsored by Upstream Bio Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The goals of this clinical study are to characterize and compare the safety, tolerability, blood levels of UPB-101 when given to healthy Japanese and non-Japanese non-East Asian (NJNEA) adults. Eligible participants will be assigned to one of the 4 planned dosing treatment groups. Treatment groups 1, 2 and 3 will consist of Japanese adults who will be administered a single subcutaneous (SC) dose of UPB-101 (at 3 different strengths). Treatment group 4 will consist of NJNEA participants who will receive a single SC dose of UPB-101. All treatment groups will enroll and run in parallel.

Read the detailed description

This is a randomized, open-label, parallel group, ethno-bridging study comparing the pharmacokinetics and safety of a single dose of UPB-101 in healthy Japanese and NJNEA adults. The study will include 4 planned dosing treatment groups. Treatment groups 1, 2 and 3 will consist of Japanese adults who will be administered a single subcutaneous (SC) dose of UPB-101 (at 3 different strengths). Treatment group 4 will consist of NJNEA participants who will receive a single SC dose of UPB-101. All treatment groups will enroll and run in parallel. Japanese participants will be enrolled and randomized on Day 1 into treatment groups 1, 2 or 3 and NJNEA participants will be assigned to treatment group 4.

Eight participants will be enrolled per treatment group, all will receive a single dose of UPB-101. Thus, a total of 32 male and female participants will be enrolled in the study (24 Japanese participants in treatment groups 1-3 and 8 NJNEA participants in treatment group 4).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Upstream Bio Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  1. Male or female, aged ≥18 to ≤40 years at the date of signing
  2. (BMI) between 18 and 25 kg/m2
  3. For Japanese (treatment groups 1, 2 and 3), participants must be:

    1. Born in Japan, holding a Japanese passport,
    2. Not living outside Japan for more than 5 years at the date of signing informed consent,
    3. Have all 4 grandparents Japanese

      For NJNEA treatment group 4, participants must be:

    4. Non-Japanese,
    5. Non-East Asian (Chinese, Korean, Mongolian or Taiwanese).
  4. Healthy, as defined by:

    1. The absence of illness and surgery within 4 weeks prior to dosing.
    2. The absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, haematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
  5. Agrees to follow the required techniques.
  6. Agrees not to donate sperm or ova from the time of the administration of study medication until three months later (120 days)

Main Exclusion Criteria:

  1. Current or recurrent disease (or condition), which may put the participant at risk, influence the results of the study, or otherwise affect their ability to participate in the study.
  2. Vital signs consistently outside the normal range at Screening or Day -1 and any other abnormal findings or vital signs, , telemetry, physical examination or laboratory evaluation of blood and urine samples that the Investigator judges as likely to interfere with the study or pose an additional risk in participating.
  3. Previous exposure or current infection with , , tuberculosis (TB), other active recent infection, or history of any untreated or unresolved infection, including parasitic infection.
  4. Pregnant or breastfeeding female.
  5. Previous exposure to the study drug or known allergy/sensitivity to any of its ingredients.
  6. Positive test results for alcohol or drugs of abuse (including cotinine) at Screening or Day -1, or history or clinical evidence of substance and/or alcohol abuse within 2 years before screening.
  7. Use of tobacco or other nicotine-containing products in any form within 3 months prior to Day 1.
  8. Any recent vaccination, prescription or over-the-counter medication, including herbal remedies or dietary supplements.
  9. Recent donation of blood or blood products.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Treatment Group 1

    Single subcutaneous injection of a low dose of UPB-101 (formerly ASP7266) in 8 Japanese participants

    Drug: UPB-101

  • Experimental
    Treatment Group 2

    Single subcutaneous injection of a medium dose of UPB-101 (formerly ASP7266) in 8 Japanese participants

    Drug: UPB-101

  • Experimental
    Treatment Group 3

    Single subcutaneous injection of a high dose of UPB-101 (formerly ASP7266) in 8 Japanese participants

    Drug: UPB-101

  • Experimental
    Treatment Group 4

    Single subcutaneous injection of a high dose of UPB-101 (formerly ASP7266) in 8 Non-Japanese Non-East Asian participants

    Drug: UPB-101

Interventions

  • UPB-101 Subcutaneous injection

    Also known as: Formerly ASP7266

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of UPB-101

    Non-compartmental analysis was used for estimation of PK parameters.

    Time frame: Baseline through Day 85

  2. Time to Maximum Observed Concentration (Tmax) of UPB-101

    Non-compartmental analysis was used for estimation of PK parameters.

    Time frame: Baseline through Day 85

  3. AUC From Time Zero up to the Last Quantifiable Concentration of UPB-101 (AUClast)

    Non-compartmental analysis was used for estimation of PK parameters. AUC = Area under the concentration-time curve

    Time frame: Baseline through Day 85

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events

    Safety endpoints included AEs, SAEs, physical examinations, clinical laboratory assessments, vital signs, ECGs including telemetry, withdrawal of participants, and early terminations.

    Time frame: Baseline through Day 85

  2. Immunogenicity Assessment of UPB-101 When Administered to Japanese and NJNEA Adults

    The immunogenicity endpoints included UPB-101 Anti-Drug Antibodies (ADAs). Outcome data is the number of participants with Low titer ADA positive results (range 60-240) observed at Day 85.

    Time frame: Baseline through Day 85

07

Results

Posted Sep 3, 2024

Participant flow

Treatment groups 1, 2, and 3 consisted of Japanese adults who were administered a single SC dose of a low, medium, or high dose of UPB-101, respectively. Treatment group 4 consisted of NJNEA participants who received a single SC dose of a high dose UPB-101.

Participant flow — Overall Study
MilestoneLow Dose, JapaneseMedium Dose, JapaneseHigh Dose, JapaneseHigh Dose, NJNEA
Started8888
Completed8888
Not completed0000

Outcome measures

PrimaryMaximum Observed Concentration (Cmax) of UPB-101

Non-compartmental analysis was used for estimation of PK parameters.

Time frame:
Baseline through Day 85
Reported as:
Mean · ug/mL
Maximum Observed Concentration (Cmax) of UPB-101
ug/mLLow Dose, JapaneseMedium Dose, JapaneseHigh Dose, JapaneseHigh Dose, NJNEA
Maximum Observed Concentration (Cmax) of UPB-10111.6 ± 2.2124.4 ± 4.7735.1 ± 12.234.9 ± 6.31
PrimaryTime to Maximum Observed Concentration (Tmax) of UPB-101

Non-compartmental analysis was used for estimation of PK parameters.

Time frame:
Baseline through Day 85
Reported as:
Median · days
Time to Maximum Observed Concentration (Tmax) of UPB-101
daysLow Dose, JapaneseMedium Dose, JapaneseHigh Dose, JapaneseHigh Dose, NJNEA
Time to Maximum Observed Concentration (Tmax) of UPB-1018.50 (4.0 to 12.0)8.00 (5.0 to 12.0)8.00 (5.0 to 14.0)7.00 (5.0 to 10.0)
PrimaryAUC From Time Zero up to the Last Quantifiable Concentration of UPB-101 (AUClast)

Non-compartmental analysis was used for estimation of PK parameters. AUC = Area under the concentration-time curve

Time frame:
Baseline through Day 85
Reported as:
Mean · day*ug/mL
AUC From Time Zero up to the Last Quantifiable Concentration of UPB-101 (AUClast)
day*ug/mLLow Dose, JapaneseMedium Dose, JapaneseHigh Dose, JapaneseHigh Dose, NJNEA
AUC From Time Zero up to the Last Quantifiable Concentration of UPB-101 (AUClast)407 ± 88.5755 ± 84.21300 ± 4751200 ± 235
SecondaryNumber of Participants With Treatment-emergent Adverse Events and Serious Adverse Events

Safety endpoints included AEs, SAEs, physical examinations, clinical laboratory assessments, vital signs, ECGs including telemetry, withdrawal of participants, and early terminations.

Time frame:
Baseline through Day 85
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events
ParticipantsLow Dose, JapaneseMedium Dose, JapaneseHigh Dose, JapaneseHigh Dose, NJNEA
Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events4478
SecondaryImmunogenicity Assessment of UPB-101 When Administered to Japanese and NJNEA Adults

The immunogenicity endpoints included UPB-101 Anti-Drug Antibodies (ADAs). Outcome data is the number of participants with Low titer ADA positive results (range 60-240) observed at Day 85.

Time frame:
Baseline through Day 85
Reported as:
Count of participants · Participants
Immunogenicity Assessment of UPB-101 When Administered to Japanese and NJNEA Adults
ParticipantsLow Dose, JapaneseMedium Dose, JapaneseHigh Dose, JapaneseHigh Dose, NJNEA
Immunogenicity Assessment of UPB-101 When Administered to Japanese and NJNEA Adults1321

Adverse events

Collected over Baseline through Day 85. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose, Japanese0/8 (0%)0/8 (0%)4/8 (50%)
Medium Dose, Japanese0/8 (0%)0/8 (0%)4/8 (50%)
High Dose, Japanese0/8 (0%)0/8 (0%)7/8 (87.5%)
High Dose, NJNEA0/8 (0%)0/8 (0%)8/8 (100%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventLow Dose, JapaneseMedium Dose, JapaneseHigh Dose, JapaneseHigh Dose, NJNEA
Upper respiratory tract infectionInfections and infestations1/80/84/84/8
HeadacheNervous system disorders0/81/82/81/8
CoughRespiratory, thoracic and mediastinal disorders0/80/80/82/8
AnemiaBlood and lymphatic system disorders0/80/80/81/8
PalpitationsCardiac disorders0/80/81/80/8
Inner ear inflammationEar and labyrinth disorders1/80/80/80/8
Vision blurredEye disorders0/80/81/80/8
COVID-19Infections and infestations1/80/80/80/8
ConjunctivitisInfections and infestations1/80/80/80/8
GastroenteritisInfections and infestations0/80/81/80/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Low Dose, JapaneseMedium Dose, JapaneseHigh Dose, JapaneseHigh Dose, NJNEATotal
Mean31.0 ± 5.6628.6 ± 5.4231.9 ± 5.4625.1 ± 3.6829.2 ± 5.1
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose, JapaneseMedium Dose, JapaneseHigh Dose, JapaneseHigh Dose, NJNEATotal
Female326415
Male562417
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Low Dose, JapaneseMedium Dose, JapaneseHigh Dose, JapaneseHigh Dose, NJNEATotal
American Indian or Alaska Native00000
Asian888125
Native Hawaiian or Other Pacific Islander00000
Black or African American00022
White00055
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Low Dose, JapaneseMedium Dose, JapaneseHigh Dose, JapaneseHigh Dose, NJNEATotal
United Kingdom888832
Body Mass Index
Body Mass Index(kg/m^2)Low Dose, JapaneseMedium Dose, JapaneseHigh Dose, JapaneseHigh Dose, NJNEATotal
Mean20.7 ± 0.8121.2 ± 1.7720.1 ± 1.7721.7 ± 1.7320.9 ± 1.5
08

Study locations

1 site
  • Richmond Pharmacology
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Apr 2023, 4 months.

Results were first posted in Sep 2024, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2022
First posted
Dec 16, 2022
StartActual
Dec 5, 2022
Primary completionActual
Apr 7, 2023
CompletionActual
May 13, 2023
Results first posted
Sep 3, 2024
Last update
Sep 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05653479
Lead sponsor
Upstream Bio Inc.
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Dec 5, 2022
Primary completion
Apr 7, 2023
Completion
May 13, 2023
Results posted
Sep 3, 2024
Last update
Sep 3, 2024

Study contacts

Chaim Brickman
study director · Upstream Bio

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verekitug

Start the discussion